Canaccord analyst David Hynes lowered the firm’s price target on ZoomInfo to $35 from $43 and keeps a Buy rating on the shares. The analyst noted growth is materially slowing, NRR likely goes sub-100%, FCF conversion is seeing headwinds, and the metrics are going to get worse before they get better. Canaccord said with the "bad news" now officially out there, we think it’s a good time to be stepping up on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZI: